Pathak Kamla, Akhtar Nida, Singh Sonam
Department of Pharmaceutics, Rajiv Academy for Pharmacy, P.O. Chhatikara, Mathura- 281001, Uttar Pradesh, India.
Pharm Pat Anal. 2015;4(6):453-74. doi: 10.4155/ppa.15.34.
Gastroretentive drug-delivery systems have the potential to prolong the gastric retention time and provide controlled/sustained release of a drug at the absorption site, thereby improving the bioavailability. Advantageous features include reduction in dose, side effects and dosing frequency. Research inputs have led to exploration of novel gastroretentive systems. The present review explores various patents issued on gastroretentive drug delivery on the basis of the therapeutic category of drugs. It traces US, EP and WIPO patents issued in the last 10 years. Various patents have revealed that gastrocarriers can effectively enhance therapeutic activity of a drug. Drugs acting on the CNS have been prominently investigated, followed by antimicrobials and locally acting drugs. Areas of future research can be drugs acting on the cardiovascular system.
胃滞留型药物递送系统有潜力延长药物在胃中的滞留时间，并在吸收部位实现药物的控释/缓释，从而提高生物利用度。其优势特性包括剂量减少、副作用减轻以及给药频率降低。研究投入促使人们探索新型胃滞留系统。本综述基于药物的治疗类别，探讨了已发布的各类胃滞留型药物递送专利。它追溯了过去10年中美国、欧洲专利局和世界知识产权组织发布的专利。各类专利表明，胃内载体可有效增强药物的治疗活性。作用于中枢神经系统的药物受到了重点研究，其次是抗菌药物和局部作用药物。未来的研究领域可能是作用于心血管系统的药物。
